Transparency and Privacy
Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead's head office in Melbourne is responsible for medical, sales and marketing activities for our products in Australia and New Zealand. The team also works closely with Gilead's network of distributors in Asia.
At Gilead, we believe in transparency. Transparency of business practices that involve financial payments, or providing other forms of value, to health care professionals is essential for building trust with all of our stakeholders. As part of our on-going commitment to transparency, Gilead collects Transparency Data including information on who we make payments to, or provide other forms of value to (eg hospitality).:
This includes collecting the following personal information about you:
- name and profession;
- business/practice address;
- a description of any services and benefits you receive from Gilead and details of any services, activities and events in respect of which you were engaged by Gilead including relevant dates;
- the amount of the financial payment or the value of any non-monetary benefit you individually receive from Gilead including the amount of air travel, accommodation costs (room rate) and registration fee paid by Gilead and/or reimbursed to you; and
- any financial payments made or non-monetary benefits given to third parties as directed by you
Gilead discloses the Transparency Data to our affiliated companies, including affiliates located outside Australia.
In accordance with the Medicines Australia Code of Conduct (the “MA Code”), or other applicable international regulations, Gilead and/or its affiliates will also publicly disclose some or all of the Transparency Data. Specifically, in accordance with transparency obligations in the MA Code, Gilead will report Transparency Data to Medicines Australia which will then be published in a manner which individually identifies you on Medicines Australia’s Central Reporting System. Gilead will give HCPs an opportunity to review and submit corrections to the Transparency Data before Gilead publishes that information.
You are responsible for obtaining any necessary approvals (e.g. from your employer or professional body) for Gilead and its affiliates to collect, use and disclose the Transparency Data.
If you accept a financial payment or non-monetary benefit from Gilead, you acknowledge that Gilead and its affiliates will collect, use and disclose the Transparency Data in accordance with above.
If disclosable under the MA Code, you are unable to prevent public disclosure of the financial payment or benefit provided to you by Gilead. If you do not want the financial payment or benefit provided to you by Gilead publicly disclosed, please do not accept financial payment or non-monetary benefits from Gilead.